EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access

Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL‐ACS Data

Joanna Lewek iD, Jacek Niedziela iD, Piotr Desperak iD, Krzysztof Dyrbuś iD, Tadeusz Osadnik iD, Piotr Jankowski iD, Adam Witkowski iD, Agata Bielecka-Dąbrowa iD, Dariusz Dudek, Marek Gierlotka iD, Mariusz Gąsior iD, Maciej Banach iD

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.123.030414 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Joanna Lewek und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Cardiology and Lipidology Medical University of Lodz Lodz Poland. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Acute Coronary Syndrome. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to compare statin monotherapy and upfront combination therapy of statin and ezetimibe in patients with acute coronary syndromes (ACSs). Methods and Results The study included consecutive patients with ACS included in the PL‐ACS (Polish Registry of Acute Coronary Syndromes), which is a national, multicenter, ongoing, prospective observational registry that is mandatory for patients with ACS hospitalized in Poland. Data were matched using the Mahalanobis distance within propensity score matching calipers. Multivariable stepwise logistic regression analysis, including all variables, was next used in propensity score matching analysis. Finally, 38 023 consecutive patients with ACS who were discharged alive were included in the analysis. After propensity score matching, 2 groups were analyzed: statin monotherapy (atorvastatin or rosuvastatin; n=768) and upfront combination therapy of statin and ezetimibe (n=768 patients). The difference in mortality between groups was significant during the follow‐up and was present at 1 (5.9% versus 3.5%; P =0.041), 2 (7.8% versus 4.3%; P =0.019), and 3 (10.2% versus 5.5%; P =0.024) years of follow‐up in favor of the upfront combination therapy, as well as for the overall period. For the treatment, rosuvastatin significantly improved prognosis compared with atorvastatin (odds ratio [OR], 0.790 [95% CI, 0.732–0.853]). Upfront combination therapy was associated with a significant reduction of all‐cause mortality in comparison with statin monotherapy (OR, 0.526 [95% CI, 0.378–0.733]), with absolute risk reduction of 4.7% after 3 years (number needed to treat=21).

Conclusions

The upfront combination lipid‐lowering therapy is superior to statin monotherapy for all‐cause mortality in patients with ACS. These results suggest that in high‐risk patients, such an approach, rather than a stepwise therapy approach, should be recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsAcute Coronary SyndromeHumansAtorvastatinRosuvastatin CalciumEzetimibePropensity Score

Stichwörter der Autor:innen

acute coronary syndromecombination therapylipidsmonotherapyprevention

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsAtorvastatinRosuvastatin CalciumEzetimibe

Autor:innen und Institutionen

  • Department of Preventive Cardiology and Lipidology Medical University of Lodz Lodz Poland.
  • Department of Cardiology and Congenital Diseases of Adults Polish Mother's Memorial Hospital Research Institute Lodz Poland.
  • 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze Medical University of Silesia Katowice Poland.
  • 3rd Department of Cardiology Silesian Centre for Heart Disease Zabrze Poland.
  • Department of Pharmacology, Faculty of Medical Sciences in Zabrze Medical University of Silesia Katowice Poland.
  • Department of Internal Medicine and Geriatric Cardiology Centre of Postgraduate Medical Education Warsaw Poland.

ORCID-Profile: Joanna Lewek, Jacek Niedziela, Piotr Desperak, Krzysztof Dyrbuś, Tadeusz Osadnik, Piotr Jankowski, Adam Witkowski, Agata Bielecka-Dąbrowa, Marek Gierlotka, Mariusz Gąsior, Maciej Banach

Zitieren

APA

Lewek, J., Niedziela, J., Desperak, P., Dyrbuś, K., Osadnik, T., Jankowski, P., Witkowski, A., Bielecka-Dąbrowa, A., Dudek, D., Gierlotka, M., Gąsior, M., & Banach, M. (2023). Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL‐ACS Data. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.030414

Vancouver

Lewek J, Niedziela J, Desperak P, Dyrbuś K, Osadnik T, Jankowski P, et al. Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL‐ACS Data. Journal of the American Heart Association. 2023. doi:10.1161/jaha.123.030414

BibTeX
@article{Lewek2023,
  author = {Lewek, Joanna and Niedziela, Jacek and Desperak, Piotr and Dyrbuś, Krzysztof and Osadnik, Tadeusz and Jankowski, Piotr and Witkowski, Adam and Bielecka-Dąbrowa, Agata and Dudek, Dariusz and Gierlotka, Marek and Gąsior, Mariusz and Banach, Maciej},
  title = {Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL‐ACS Data},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.123.030414}
}
Kostenlos starten →